Allogene Therapeutics Stock Story
ALLO Stock | USD 3.46 0.05 1.42% |
About 68% of Allogene Therapeutics' investor base is looking to short. The analysis of the overall investor sentiment regarding Allogene Therapeutics suggests that many traders are alarmed. Allogene Therapeutics' investor sentiment overview provides quick insight into current market opportunities from investing in Allogene Therapeutics. The current market sentiment, together with Allogene Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Allogene Therapeutics stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Allogene Therapeutics stock news, alerts, and headlines are usually related to its technical, predictive, social, and fundamental indicators. It can reflect on the current distribution of Allogene daily returns and investor perception about the current price of Allogene Therapeutics as well as its diversification or hedging effects on your existing portfolios.
Allogene |
Requested story not found. it has been either deleted or moved. View all stories for Allogene Therapeutics.
Allogene Therapeutics Latest Timeline
Allogene Therapeutics is listed for 3.46. About 22.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.25. Some equities with similar Price to Book (P/B) outperform the market in the long run. Allogene Therapeutics recorded a loss per share of 2.09. The entity had not issued any dividends in recent years.Check out Allogene Therapeutics Hype Analysis, Allogene Therapeutics Correlation and Allogene Therapeutics Performance. To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Complementary Tools for Allogene Stock analysis
When running Allogene Therapeutics' price analysis, check to measure Allogene Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Allogene Therapeutics is operating at the current time. Most of Allogene Therapeutics' value examination focuses on studying past and present price action to predict the probability of Allogene Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Allogene Therapeutics' price. Additionally, you may evaluate how the addition of Allogene Therapeutics to your portfolios can decrease your overall portfolio volatility.
Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
Equity Valuation Check real value of public entities based on technical and fundamental data | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format |
Is Allogene Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.09) | Revenue Per Share 0.001 | Quarterly Revenue Growth (0.55) | Return On Assets (0.27) | Return On Equity (0.56) |
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allogene Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.